GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025
Updated: Sunday, December 14, 2025 (markets closed; prices reflect the most recent close). GSK plc (LSE: GSK / NYSE: GSK) heads into mid‑December with a rare “cluster catalyst” setup: multiple fresh European regulator panel endorsements, a new U.S. label expansion for an antibiotic, and steady buyback activity. That combination doesn’t guarantee a breakout (stocks are fickle creatures), but it does give investors a clearer map of what could move GSK shares in the days ahead. As of the latest available trading data, GSK’s U.S. ADR last traded around $48.81. In London, the most recent close was 1,824.5p (Dec. 12, 2025).